Clinical Trial Update: A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

View source ↗

Summary

A post-authorization safety study (PASS) is being conducted to monitor the safety of lonapegsomatropin in patients with growth hormone deficiency; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Skytrofa (lonapegsomatropin)

Snippet

Sponsor: Ascendis Pharma Endocrinology Division A/S | Conditions: Growth Hormone Deficiency | Status: RECRUITING